STI Stock Trade Intelligence
OIL

OPTISCAN IMAGING LIMITED

Health Care · ASX:OIL
$0.1350
▼ -3.57%
Market cap
$141M
Turnover
$31,122
Last price
$0.1350
Day change
-3.57%
Announcements
13
Range, past year
Open 0.085 · Low 0.078 · Now 0.135 · High 0.200
Open OIL in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

OIL momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-09-28.
Momentum quality
28/100
Wyckoff phase
Accumulation10d
Trend stage
Distribution
1 Day
-3.6%
1 Week
-3.6%
1 Month
-12.9%
1 Year
+64.6%
RSI
42
Avg daily range
9.4%

OPTISCAN IMAGING LIMITED scores 28 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Distribution.

On the Wyckoff cycle it sits in Accumulation, where it has been for 10 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -33.3%
  • High volatility (ATR 9.4%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
OIL appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

OIL announcements

Recent price-sensitive releases.
  • 2026-09-10 Significant Milestone Reached in ACL Digital Pathology Study Progress Report
  • 2026-09-01 Optiscan Initiates Head and Neck Cancer Study in the US Progress Report
  • 2026-08-25 Preliminary Final Report Preliminary Final Report
  • 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-22 Optiscan Signs New Research Agreement for Breast Study
  • 2026-07-21 Head and Neck Study Progressing Ahead of Schedule
  • 2026-07-07 Optiscan Launches InSpecta Device for Veterinary Medicine
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.